On October 29, 2026, Bambusa Therapeutics, a Boston-based clinical-stage company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, announced the pricing of its upsized initial public offering of 10,555,555 shares of its common stock at a public offering price of $16.00 per share. Bambusa’s common stock began trading on the Nasdaq Global Select Market today under the ticker symbol “BBTX.” Wilson Sonsini Goodrich & Rosati advised Bambusa on the transaction.

The Wilson Sonsini team that advised Bambusa on the transaction includes:

Corporate
Jennifer Fang
David Sharon
Karen Deschaine
Tony Jeffries
Tamara Brightwell
Tamara Labanowski
Erin Wolter
Cliff Gilman

Employee Benefits and Compensation
Megan Schilling
Dani Nazemian
Sophia Friedfertig

Regulatory
Eva Yin

Intellectual Property and Technology Transactions
Norm Hovijitra
Lou Lieto
Kexi Wang
Ying Chen

For more information, please see Bambusa’s news release.